...
首页> 外文期刊>Cancers >Cancer Biomarkers: Are We Ready for the Prime Time?
【24h】

Cancer Biomarkers: Are We Ready for the Prime Time?

机译:癌症生物标志物:我们准备好迎接黄金时间了吗?

获取原文
           

摘要

A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. In cancer, a biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker might be either a molecule secreted by a tumor or it can be a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for cancer diagnosis, prognosis and epidemiology. These markers can be assayed in non-invasively collected biofluids. However, few cancer biomarkers are highly sensitive and specific for cancer detection at the present time. Consequently, biomarkers are not yet ready for routine use due to challenges in their clinical validation for early disease detection, diagnosis and monitoring to improve long-term survival of patients.
机译:生物标志物是客观测量和评估的特征,可作为正常生物过程,致病过程或对治疗干预的药理反应的指标。在癌症中,生物标志物是指指示体内癌症存在的物质或过程。生物标志物可能是肿瘤分泌的分子,也可能是机体对癌症存在的特异性反应。遗传,表观遗传,蛋白质组学,糖类和影像学生物标志物可用于癌症的诊断,预后和流行病学。可以在非侵入性收集的生物流体中测定这些标记。然而,目前很少有癌症生物标志物对癌症检测高度敏感和特异。因此,由于生物标志物在临床验证方面存在挑战,无法用于常规疾病的早期检测,诊断和监测,以提高患者的长期存活率,因此尚未准备好常规使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号